Ondansetron is named as an intervention in 3 current clinical trials in our China and USA registers. 3 are recruiting patients now. The most common phase is Phase 4. The sponsor with the most trials is Karuna Therapeutics, Inc., a Bristol Myers Squibb company (1). The most-studied condition is Healthy Volunteers.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy Volunteers
NCT07681076 · Healthy Volunteers
|
Phase 4 | Recruiting | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | USA |
|
The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities
NCT07381634 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC), IrAE
|
Phase 2 | Recruiting | First Affiliated Hospital of Wenzhou Medical University | China |
|
Ondanstron Weekly vs Every 3 Weeks for Prevention of Nausea and Vomiting Induced by Chemotherapy Combined With PD-1 Blockade
NCT06080880 · ClinicalTrials.gov ↗ · Nausea With Vomiting Chemotherapy-Induced
|
Not applicable | Recruiting | Hubei Cancer Hospital | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 1 |
| Hubei Cancer Hospital | 1 |
| First Affiliated Hospital of Wenzhou Medical University | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 2 |
| Clinical trials in USA | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our China and USA registers name Ondansetron as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 3 of the 3 trials are recruiting: 2 with sites in China and 1 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Karuna Therapeutics, Inc., a Bristol Myers Squibb company (1), Hubei Cancer Hospital (1) and First Affiliated Hospital of Wenzhou Medical University (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Ondansetron works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Ondansetron works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Ondansetron (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.